designed for ophthalmic disease.
• One-time treatment
• 10-minute procedure
• No seed left behind
• Accurate dosing
• Precision targeting
The location of disease activity (wet-AMD type) determines the effectiveness of the treatment.
Patients who do not respond well to anti-VEGF treatment typically suffer from occult and minimally classic lesions, located below the retinal pigment epithelium (RPE).
BetaCurve curves around the back of the eye and precisely delivers therapeutic beta radiation to the diseased area guided by a fiber optic light source.
Upper layer disease activity above the RPE (classic type) responds well to anti-VEGF injections.
The BetaCurve is designed to target the occult and PCV disease from the nearest location with precision delivery.
Radiation oncologists affirm SMD's choice of strontium-90
(beta radiation) due to its reliable performance.
Strontium-90 is a stable source of beta radiation.
Beta radiation is ideally suited to treat diseased tissues due to its limited and predictable
BetaCurve is designed to enable a retina surgeon to deliver the appropriate dose of
therapeutic radiation at the precise location.
A new approach with potentially breakthrough results
PCV is a significantly large subset type of wet-AMD that requires a new treatment paradigm.
PCV exhibits a branching vascular network with numerous polypoids (micro-aneurysms). Choroidal vasculature and polypoids are known to be resistant to the anti-VEGF mechanism. Ultimately, PCV disease progression tends to cause vision-threatening hemorrhages.
SMD's early feasibility studies have shown the ability of beta radiotherapy to eliminate polyps, reduce lesion size, dry up subretinal fluid, and stabilize or improve visual acuity in recalcitrant PCV patients who have received years of anti-VEGF therapy.
Anti-VEGF may improve vision but does not treat the root cause.
BetaCurve treats the root cause.